Miller A B
Department of Preventive Medicine and Biostatistics, University of Toronto, Canada.
Biomed Pharmacother. 1988;42(7):439-42.
The ethical principles underlying screening are reviewed. It is concluded that the ethical requirements for the introduction of screening are stringent, and that screening should not be offered in the absence of unequivocal evidence of effectiveness except in a carefully conducted research study. Part of the reasons for this are the risks associated with screening, which extend beyond the risk of the test itself, to those associated with invitations for screening, false reassurance for false negatives, the diagnostic process and the problem of false positives, and the overtreatment of those with borderline abnormalities. Finally, the benefits expected from screening are considered, especially reduction in mortality from the disease, but also reduction in incidence if a precursor is detected by the test, less radical treatment for cases detected, reassurance for those who test true negative, and resource savings, though it has to be demonstrated that these exceed resource costs.
本文回顾了筛查所依据的伦理原则。得出的结论是,开展筛查的伦理要求十分严格,在缺乏明确疗效证据的情况下,不应进行筛查,除非是在精心开展的研究中。部分原因在于筛查存在风险,这些风险不仅包括检测本身的风险,还涉及筛查邀请、假阴性的错误安慰、诊断过程、假阳性问题以及临界异常者的过度治疗等相关风险。最后,考量了筛查预期带来的益处,特别是疾病死亡率的降低,但若检测发现了前驱病变,还包括发病率的降低、所发现病例的治疗手段不那么激进、检测结果为真阴性者的安心,以及资源节约,不过必须证明这些益处超过资源成本。